Takai S, Takeda K, Nakano Y, Karasawa T, Furugoori J, Sasaki Y, Tsubaki S, Higuchi T, Anzai T, Wada R, Kamada M
Department of Animal Hygiene, School of Veterinary Medicine and Animal Sciences, Kitasato University, Towada, Aomori, Japan.
J Clin Microbiol. 1997 Jul;35(7):1904-8. doi: 10.1128/jcm.35.7.1904-1908.1997.
To investigate the emergence of rifampin resistance in Rhodococcus equi strains isolated from foals and their environment in Japan, we compared the in vitro antimicrobial susceptibilities to rifampin of 640 isolates from 64 infected foals and 98 soil isolates from their horse-breeding farms. As a control, 39 human isolates from patients with and without AIDS were also tested for susceptibility to rifampin. All of the isolates showed rifampin sensitivity, except isolates from one infected foal and two patients with AIDS that showed rifampin resistance. To investigate the emergence of rifampin-resistant R. equi in the infected foal, which had received rifampin monotherapy for a month before euthanasia, 99 isolates of R. equi from the lesions and 20 isolates from the intestinal contents of the one foal with rifampin-resistant organisms were analyzed for rifampin susceptibilities, pathogenicities, and ribotypes. Of the 99 isolates from the lesions, all of which were virulent R. equi strains containing a virulence plasmid with a size of 85 or 90 kb, 90 (91%) isolates were rifampin resistant (MIC, > or = 12.5 microg/ml). On the other hand, of the 20 isolates from the intestinal contents, 11 (55%) isolates showed rifampin resistance (MIC, > or = 25 microg/ml), and 5 of them were avirulent R. equi strains. Among these 101 rifampin-resistant R. equi isolates with and without virulence plasmids characterized by ribotyping, 58 were type I, 20 were type II, 11 were type III, and 12 were type IV. These results demonstrated that at least eight different rifampin-resistant R. equi strains emerged concurrently and respectively from the different lesions and intestinal contents of the infected foal.
为研究从日本驹及其环境中分离出的马红球菌菌株中利福平耐药性的出现情况,我们比较了从64匹感染驹中分离出的640株菌株以及从其养马场土壤中分离出的98株菌株对利福平的体外抗菌敏感性。作为对照,还检测了39株来自艾滋病患者和非艾滋病患者的人类分离株对利福平的敏感性。除了1株感染驹和2例艾滋病患者的分离株显示利福平耐药外,所有分离株均对利福平敏感。为研究在安乐死之前接受了一个月利福平单一疗法的感染驹中利福平耐药马红球菌的出现情况,对来自该驹病变部位的99株马红球菌分离株和来自肠道内容物的20株分离株进行了利福平敏感性、致病性和核糖体分型分析,该驹存在利福平耐药菌。从病变部位分离出的99株菌株均为含有大小为85或90 kb毒力质粒的强毒马红球菌菌株,其中90株(91%)分离株对利福平耐药(最低抑菌浓度,≥12.5 μg/ml)。另一方面,从肠道内容物中分离出的20株菌株中,11株(55%)分离株显示利福平耐药(最低抑菌浓度,≥25 μg/ml),其中5株为无毒力马红球菌菌株。在这些通过核糖体分型鉴定的101株有或没有毒力质粒的利福平耐药马红球菌分离株中,58株为I型,20株为II型,11株为III型,12株为IV型。这些结果表明,至少8种不同的利福平耐药马红球菌菌株同时并分别从感染驹的不同病变部位和肠道内容物中出现。